liver cancer
Conditions
Interventions
DEB-TACE:Nil
Sponsors
Sichuan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The patients were 18-80 years old, and the estimated survival time was more than 3 months; 2. Gender is not limited; 3. HCC patients were diagnosed according to the criteria for diagnosis and treatment of primary liver cancer (version 2019) or pathological biopsy; 4. HCC lesions were in BCLC-B/C stage; 5. The child Pugh score of liver function was less than or equal to 7; 6. ECOG score <= 1; 7. The patients who did not receive chemoradiotherapy, ablation, immunotherapy and molecular targeted therapy before DEB-TACE for the first time; 8. Patients and / or family members agreed to participate in the clinical trial and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. The main portal vein was completely embolized with less collateral vessels; 2. The coagulation function decreased seriously and could not be corrected; 3. The heart, lung, kidney, brain and other organs were seriously incompetent; 4. The tumor volume was more than 70% of the liver volume; 5. Patients with history of other tumors; 6. HCC recurred after surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor efficacy;miRNA; | — |
Countries
China
Contacts
Public ContactXuegang Yang
Sichuan Cancer Hospital
Outcome results
None listed